Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors

被引:2
|
作者
Suthar, M. P. [1 ]
Patel, M. M. [2 ]
机构
[1] Ganpat Univ, Shree SK Patel Coll Pharmaceut Educ & Res, Dept Biotechnol, Kherva 382711, India
[2] Kalol Inst Pharm, Kalol 382721, India
关键词
Cyclin-dependent kinase 2; histone H1; luminescence; assay; optimization; PROTEIN-KINASES;
D O I
10.4103/0250-474X.70472
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclin-dependent kinases are most extensively studied targets for cancer chemotherapy since the tumor cells exhibit false checkpoints and can proliferate even if the genome is compromised. Cyclin-dependent kinases ensure the tight regulation of the cell cycle execution by mediating phosphorylation of cellular proteins. Deregulation of the cyclin-dependent kinase 2 activity by cellular and external factors leads to many diseases like cancers. Different methods like radiolabeled, fluorescence and luminescence are available for screening of library of compounds against kinases. However, bioluminescent methods offer several advantages like low background and no effect of fluorescent compound interference. Present study is focused on development, optimization and validation of cyclin-dependent kinase 2 assay which is suitable for identification potent and selective, ATP competitive and non-competitive inhibitors of cyclin-dependent kinase 2. The aim of present investigation was to optimize the assay for cyclin-dependent kinase 2/cylin A and cyclin-dependent kinase 2/cyclin E with use of bioluminescence based biochemical reaction. Both cyclin-dependent kinase 2 which are cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E complexes, have different affinity for ATP. Therefore, both isoform analogs of cyclin-dependent kinase 2 were optimized separately. Optimum cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E concentration were found to be 250 ng/well and 200 ng/well, respectively. Optimum substrate (histone H1) concentration was found to be 2.5 mg/ml for both cyclin-dependent kinase 2 analogs. Optimum reaction time was found to be 20 min for both cyclin-dependent kinase 2/cyclin complexes.
引用
收藏
页码:290 / 294
页数:5
相关论文
共 50 条
  • [41] Cyclin-dependent kinase 7 inhibitors in cancer therapy
    Wang, Minmin
    Wang, Tianyu
    Zhang, Xiangyu
    Wu, Xiaoxing
    Jiang, Sheng
    FUTURE MEDICINAL CHEMISTRY, 2020, 12 (09) : 813 - 833
  • [42] Cyclin-dependent kinase inhibitors move into Phase III
    Guha, Malini
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (12) : 892 - 894
  • [43] Cyclin-dependent kinase inhibitors (CKIs) and hematological malignancies
    Baghdassarian, N
    Ffrench, M
    HEMATOLOGY AND CELL THERAPY, 1996, 38 (04): : 313 - 323
  • [44] Cyclin-dependent kinase inhibitors for the treatment of lung cancer
    Qin, Angel
    Reddy, Haritha G.
    Weinberg, Frank D.
    Kalemkerian, Gregory P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (08) : 941 - 952
  • [45] Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma
    Ramakrishnan, Vijay G.
    Kumar, Shaji K.
    CANCER JOURNAL, 2016, 22 (01): : 7 - 11
  • [46] PRECLINICAL AND CLINICAL DEVELOPMENT OF CYCLIN-DEPENDENT KINASE AND CHECKPOINT KINASE INHIBITORS
    Shapiro, G. I.
    ANNALS OF ONCOLOGY, 2010, 21 : 27 - 27
  • [47] Biolayer Interferometry Assay for Cyclin-Dependent Kinase-Cyclin Association Reveals Diverse Effects of Cdk2 Inhibitors on Cyclin Binding Kinetics
    Tambo, Carrie S.
    Tripathi, Sarvind
    Perera, B. Gayani K.
    Maly, Dustin J.
    Bridges, Alexander J.
    Kiss, Gert
    Rubin, Seth M.
    ACS CHEMICAL BIOLOGY, 2023, : 431 - 440
  • [48] Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors
    Li, XY
    Huang, P
    Cui, JJ
    Zhang, J
    Tang, C
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (11) : 1939 - 1942
  • [49] A computational model of binding thermodynamics: The design of cyclin-dependent kinase 2 inhibitors
    Sims, PA
    Wong, CF
    McCammon, JA
    JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (15) : 3314 - 3325
  • [50] Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation
    Gondeau, C
    Gerbal-Chaloin, S
    Bello, P
    Aldrian-Herrada, G
    Morris, MC
    Divita, G
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (14) : 13793 - 13800